Business Wire

CA-GLOBALLOGIC

Share
Inspira Technologies Selects GlobalLogic for Software Development of its Early Extracorporeal Respiratory Support System that Functions as an "Artificial Lung"

GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Inspira Technologies to develop an algorithm-enhanced digital platform powering the ART device — an Early Extracorporeal Respiratory Support system targeting respiratory failure patients such as those diagnosed with COVID-19. The project underscores GlobalLogic’s deep expertise in Class II and Class III software creation for medical devices that must meet strict regulatory requirements.

Inspira Technologies created the ART, a novel low-flow early extracorporeal approach to address the significant patient population whose condition continues to deteriorate following noninvasive ventilation. As of today, the only treatment available for them after noninvasive ventilation is the highly invasive mechanical ventilation. The ART device utilizes a hemo-protective flow approach designed to rebalance oxygen saturation levels while patients are awake and breathing spontaneously, potentially minimizing the need for mechanical ventilation. The ART is designed to enrich ~200cc of blood at any given point, elevating the oxygen saturation levels in one minute.

GlobalLogic will support Inspira in the development of the ART control platform’s algorithms responsible for monitoring and managing the early rebalancing of the patient’s oxygen saturation levels. These algorithms will also activate and control proprietary technologies and data collected from advanced sensors that measure oxygen saturation, blood temperature, hemoglobin, and hematocrit levels as well as blood pressure and flow. Inspira Technologies notes that the ART could potentially minimize the need for mechanical ventilators for hypoxemic patients, such as COVID patients. Additionally, GlobalLogic will be leading the verification testing of these systems.

“Software plays an increasingly more crucial role in driving the overall efficacy of medical devices today. It also enhances the patient engagement with and medical staff’s use of such technologies,” said Shashank Samant, President & CEO, GlobalLogic. “For nearly twenty years, we’ve worked with world-renowned medical device manufacturers as well as start-ups in today’s MedTech innovation hotspots. We’re honored to have the opportunity to play such a pivotal role in bringing to market another disruptive technology, the ART. Particularly at such a critical time when there is a dire need for advanced treatment options.”

GlobalLogic possesses deep competencies centered around key medical device capabilities: device performance; data collection and analysis; and intuitive medical personnel and patient experiences. Specific to the ART, GlobalLogic’s engineering contributions will help Inspira Technologies produce a digitally enhanced artificial lung while empowering medical staff with vital patient stats needed to easily monitor progress and effectiveness.

“It was imperative that we find a partner with both specialized MedTech capabilities and the scale needed to meet our design objectives as we are committed to bring to market a much-needed technology — filling a critical gap in today’s medical treatment options for respiratory failure patients who continue to deteriorate after treatment with noninvasive ventilation devices. Our decision to partner with GlobalLogic was driven by its proven ability in the medical device landscape and the capacity to meet aggressive time-to-market requirements with reliable solutions,” explained Dagi Ben-Noon, CEO, Inspira Technologies.

ART is currently in development with anticipated regulatory submission of its ART ECLS at the end of 2022.

About GlobalLogic

GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise — we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the healthcare and life sciences, communications, financial services, automotive, technology, media and entertainment, manufacturing, and semiconductor industries. GlobalLogic is a Hitachi Group Company.

Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective early extracorporeal respiratory support system with an intent to function as an “Artificial Lung” for deteriorating respiratory patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are awake and breathing, potentially minimizing the patient’s need for mechanical ventilation. The Company’s product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA). For more information, please visit our corporate website: https://inspira-technologies.com/ .

Link:

ClickThru

Social Media:

https://www.facebook.com/GlobalLogic/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Transition Industries Signs Strategic Agreements for the Pacifico Mexinol Project, the Largest Standalone Ultra-Low Carbon Chemical Production Facility in the World30.6.2025 20:30:00 CEST | Press release

Pacifico Mexinol project, a 6,130 MT per day ultra-low carbon methanol production facility worth more than US$3.3b will be located near Topolobampo, Ahome, Sinaloa. Once operational in 2029, Pacifico Mexinol is poised to be the largest standalone ultra-low carbon chemical production facility in the world. Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America, held a signing event for an Engineering, Procurement, and Construction (EPC) contract with the consortium of Samsung E&A Co., Ltd. (Samsung E&A), Grupo Samsung E&A Mexico, S.A. de C.V., and Techint Engineering and Construction for the Pacifico Mexinol project located in Ahome, Sinaloa, Mexico, which is contingent upon the fulfillment of customary conditions precedent and obtainment of all required approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630940954/en/ MAIRE group’s techn

Westinghouse and ITER Sign a $180M Contract to Advance Nuclear Fusion30.6.2025 15:45:00 CEST | Press release

The contract includes the assembly of the fusion reactor’s vacuum vessel, a key milestone which gets the project closer to replicating fusion energy on Earth Westinghouse Electric Company and ITER signed a contract for $180 million for the assembly of the vacuum vessel for the fusion reactor. This is a key milestone in the construction of the ITER reactor, leading the way toward the use of fusion as a practical future source of reliable carbon-free energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630497810/en/ The ITER Tokamak pit with the two vacuum vessel sector modules installed. Westinghouse has participated in the fabrication of the sectors of the vacuum vessel, as part of the Fusion for Energy (F4E) Consortium with its partners Ansaldo Nucleare and Walter Tosto. Westinghouse will be responsible for completing the vacuum vessel which is ITER’s most critical component: a hermetically sealed, double-walled steel

Monetate Acquires SiteSpect to Deliver AI-Native Personalization and Testing at Enterprise Scale30.6.2025 15:00:00 CEST | Press release

Monetate’s Real-Time Personalization Unites with SiteSpect’s Zero-Flicker Testing to Optimize Digital Experiences with Unmatched Speed, Precision, and SecurityNow Global Ecommerce and Digital Experience Leaders Can Access a Best-in-Class, Enterprise-Grade Personalization, Testing, and Optimization Platform Monetate, the leading AI-driven personalization platform, today announced it has acquired SiteSpect, a leader in A/B testing, to drive next-generation digital experience optimization. This acquisition accelerates Monetate’s vision to deliver intelligent, intentional, and individualized experiences at scale, powered by agentic AI and backed by the industry’s most advanced, enterprise-grade infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630514541/en/ The combination of Monetate’s real-time personalization and SiteSpect’s zero-flicker testing will yield an industry-first solution for enterprise-grade person

SS&C Blue Prism Recognized as a Gartner® Magic Quadrant™ RPA Leader for the Seventh Consecutive Year30.6.2025 15:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that SS&C Blue Prism has been recognized as a Leader in the 2025 Gartner Magic Quadrant for Robotic Process Automation (RPA). “We’re delighted SS&C Blue Prism has been named a Leader in the Gartner Magic Quadrant for Robotic Process Automation for the seventh year running,” said Bill Stone, CEO and Chairman of SS&C Technologies. “SS&C Blue Prism combines market-leading RPA and orchestration technologies with the latest artificial intelligence so organizations can tackle more complex tasks and dynamic business processes. We’ve scaled to more than 2,700 digital workers and AI agents across our own operations, resulting in over $200 million in annual savings. With SS&C leading the charge on deployment, customers can be confident in rolling out SS&C’s automation solutions securely, effectively, and responsibly.” More than 2,800 companies worldwide leverage SS&C Blue Prism for AI-powered automation, helping organizations delive

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content130.6.2025 14:00:00 CEST | Press release

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency1U.S. Commercialization of GAMMAGARD LIQUID ERC Projected to Begin in 2026Company Announces Future Manufacturing Discontinuation End Date for Takeda's First-Generation Low-IgA Product, A Freeze-Dried Formulation in Company’s Differentiated Immunoglobulin Portfolio of Ready-to-Use Liquids2 Takeda(TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administratio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye